Gregory L. Verdine (born June 10, 1959) is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor.

Verdine is the co-inventor with Christian Schafmeister of stapled peptides, a new class of drugs that combines the versatile binding properties of monoclonal antibodies with the cell-penetrating ability of small molecules.

A close analog of a stapled peptide drug invented in the Verdine Lab, sulanemadlin (ALRN-6924), is a first-in-class dual MDM2/MDMX inhibitor currently in Phase II clinical development by Aileron Therapeutics,[4] which he co-founded in 2005.

His companies have succeeded in developing two FDA-approved drugs, romidepsin and paritaprevir, which are, respectively, an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs), and an acylsulfonamide inhibitor that is used to treat chronic hepatitis C. Verdine received a Bachelor of Science in Chemistry from Saint Joseph's University and a PhD in Chemistry from Columbia University, working under Koji Nakanishi and Maria Tomasz.

In his academic research, Verdine made fundamental discoveries about how organisms manage their genomes: how they tag specific cell types and conduct search-and-destroy operations for cancer-causing abnormalities.

[13] To translate his discoveries into therapeutics, Verdine has founded or co-founded numerous public biotech companies including Variagenics, Enanta, Eleven Bio, Tokai, Wave Life Sciences, and Aileron.

[16] Founded alongside FogPharma in 2016, LifeMine seeks to discover, characterize, and translate into medicine bioactive compounds in fungal genomes.